Verona Pharma’s COPD Phase 2a Trial Gets Underway
Verona Pharma plc, a United Kingdom-based biopharmaceutical company dedicated to therapies for respiratory disorders, recently announced the completion of the patient enrollment phase in two Phase 2a clinical trials assessing the company’s product RPL554. RPL554 is a “first-in-class” inhaled drug under development for respiratory conditions such as chronic obstructive…